Advertisement

Topics

Companies Related to "An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial" [Most Relevant Company Matches] RSS

14:08 EST 9th December 2018 | BioPortfolio

Here are the most relevant search results for "An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial" found in our extensive corporate database of over 50,000 company records.

Showing "Observational Follow Study Incidence Cancer Mortality Patients From" Companies 1–25 of 6,600+

Extremely Relevant

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...


Relevant

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Tennessee Cancer Patient Coalition

The Tennessee Cancer Patient Coalition’s mission is to serve as an advocate for cancer patients and their caregivers. The Coalition believes cancer patients should have the opportunity to make informed decisions about their care and have equal access to the most advanced treatment methods available. Proton Therapy is the most advanced form of radiatio...


Styrene Information and Research Center (SIRC)

1 Collins, JJ, Bodner, KM, Bus, JS. Cancer Mortality of Workers Exposed to Styrene in the US Reinforced Plastics and Composite Industry. Epidemiology, March 2013, 24(2), 195-203. http://journals.lww.com/epidem/Abstract/2013/03000/Cancer_Mortality_of_Workers_Exposed_to_Styrene_in.5.aspx

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

The German Breast Group and Celgene Corporation

GBG is a large independent academic network of over 500 study centers in Germany with the world- wide largest experience in conducting neoadjuvant breast cancer trials. Since 1998, with joined forces from AGO-B, over 10.000 patients participated in the neoadjuvant “Gepardo” trial series. GBG has recruited at totality of over 35.000 patients to tr...

PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

Colonix Medical Limited

Colonix Medical Limited has pioneered and refined a new system for the early detection / screening of colorectal cancer and other bowel diseases such as IBD. This system can be used for both symptomatic and non symptomatic patients. Colorectal cancer is often referred to as ‘the silent killer’. If detected early, colorectal cancer treatments are effective and after treatment most sufferers ca...

Oncolab Incorporated

An Innovative Aid in Early Cancer Diagnosis and Follow up Oncolab provides the FDA approved AMAS blood test, helping health care professionals to diagnose cancer, and to follow up during treatment. In studies of more than 8,000 patients, the AMAS® Test was found to be 95% accurate and unique for its diverse use as a diagnostic tool regarding all non-terminal cancers. In some cases, the AMAS® t...

Genetronics Biomedical

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiv...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

Cancer Prevention Coalition

On April 22, 2010, Senators Dianne Feinstein and Sam Brownback urged the Senate to pass the 2009 Lung Cancer Mortality Reduction Act. This stated that "lung cancer is the leading cause of cancer death in both men and women, accounting for 28 percent of all cancer deaths." The Act also warned that "two-thirds of nonsmokers diagnosed with lung cancer are wom...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

MemorialCare Todd Cancer Institute

The MemorialCare Todd Cancer Institute (TCI) is dedicated to the early diagnosis, treatment, research and education of patients with cancer. TCI specializes in the divisions of gynecology, breast, thoracic, gastrointestinal and urinary cancers. TCI also offers psychosocial oncology services to help patients improve their quality of life while dealing with ...

Navigating Cancer

Navigating Cancer is dedicated to empowering cancer patients to navigate their best care. Navigating Cancer, www.navigatingcancer.com, is a free web application that offers personalized tools and authoritative cancer resources to help patients take control of their health and partner more closely with their physicians, support network and other like patien...

Noldus Information Technology

Noldus Information Technology is a leading developer of software tools and integrated solutions for the study of human and animal behavior. Technologies include advanced digital video, observational data collection, video tracking, physiological data acquisition, eye tracking, user-system interaction logging, facial expression data analysis, and pattern detection. With global headquarters in The N...

The North Shore-LIJ Cancer Institute

The North Shore-LIJ Cancer Institute is one of the largest cancer providers in the New York metropolitan area. With 200 physicians, the Cancer Institute diagnoses and/or treats more than 16,000 cancer patients each year. Its multidisciplinary teams develop individualized treatment plans that address patients’ physical and emotional needs through 12 di...

Queensland Cancer Fund

The Queensland Cancer Fund was established in 1961 in response to a desperate need in the community. Cancer mortality was on the increase and available resources could not cope with the problem. A small group of concerned people decided to form the Queensland Cancer Fund and began planning a strategy for raising funds to combat the disease and provide adequate treatment facilities for cancer patie...

Longboat Clinical

Longboat is a clinical trials software company dedicated to generating better study outcomes by creating a complete support structure for site staff, patients, monitors, and study teams - where protocol compliance becomes easy and instinctive. In the complex world of clinical development, Longboat’s cloud-based site and patient engagement platform emp...

GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd, is the leading global provider of ambulant healthcare services for clinical trials to government agencies and the world’s biopharmaceutical and medical device companies engaged in all phases of product development. GlobalCare provides innovative, GCP-compliant services by conducting selected study visits in the home or...

Nagourney Cancer Institute

The Nagourney Cancer Institute is a clinical research center that has pioneered the study of human tumor tissue for individualized cancer patient drug selection and has facilitated cancer drug discovery.

Hunter Immunology Limited

Our lead product is a vaccine currently called HI-164OV. It works by controlling bacterial colonisation of airways damaged by inhaled toxins. It has been developed to treat patients with Chronic Obstructive Pulmonary Disease (COPD) which includes bronchitis and emphysema. HI-164OV could help improve the lives of over one million Australians with COPD, and contribute towards saving Australia ...

Beckstrand Cancer Foundation

Beckstrand Cancer Foundation is a 501(c)(3) organization founded in 1974 by Dr. Grant Beckstrand and a group of doctors specializing in the treatment and care of cancer patients. The Foundation’s goal has been to improve and enhance the quality of life for cancer patients and their families, a mission achieved through unique programs which provide fin...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...


More From BioPortfolio on "An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks